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Microabstract 
The regulation of dihydropyrimidine dehydrogenase (DPD)  in cancers with 
mutated epidermal growth factor receptor (EGFR) is unknown. In this study, the 
clinicopathological analysis of 96 NSCLC patients and cell based studies reveal 
high DPD expression in EGFR mutated tumors. This finding should be taken into 
account when designing a therapeutic strategy for the treatment of NSCLC. 
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Abstract 
Background: It has been shown that 5-fluorouracil (5-FU) sensitivity in non-small 
cell lung cancer (NSCLC) is associated with epidermal growth factor receptor 
(EGFR) mutation status. However, the relationship between dihydropyrimidine 
dehydrogenase (DPD), a 5-FU degrading enzyme, and EGFR mutation status is 
unknown. Here, we focus on clinicopathological factors and in vitro correlations 
between DPD expression and EGFR mutation status. 
Patients and Methods: EGFR mutations and mRNA levels of DPD and 
thymidylate synthase (TS) were analyzed in 47 resected NSCLCs by laser capture 
microdissection. In addition, relationships between EGFR mutation status and the 
immunohistochemical expression of DPD and TS in 49 patients with primary 
NSCLC, treated with a 5-FU derivative of S-1 postoperatively, were examined. 
Correlations between clinicopathological factors were evaluated. The effect of 
EGF on DPD expression was also investigated in vitro in various cell lines. 
Results: Adenocarcinoma in situ (AIS) showed significantly higher DPD mRNA 
levels and more EGFR mutation frequency than other histological types (P<.05). 
DPD immuno-positive cases were more frequently observed in adenocarcinoma, in 
females and in non-smokers. DPD immune-positive cases were correlated with 
EGFR mutation status (P<.003). The prognoses of EGFR wild-type and mutated 
populations were similarly favorable with postoperative S-1 treatment, which 
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overcomes the problem of 5-FU degradation in mutated EGFR. In vitro, EGFR 
mutated cell lines showed high DPD mRNA and protein expression. Conclusions: 
High DPD expression was shown to be correlated with EGFR mutation in 
adenocarcinoma cells and tissues. This finding should be taken into consideration 
when using 5-FU to treat NSCLC patients.  
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Introduction 
The current standard regimen of chemotherapy for the treatment of wild types 
of epidermal growth factor receptor (EGFR) and echinoderm microtubule-
associated protein-like 4 anaplastic lymphoma kinase (EML4ALK) non-small cell 
lung cancer (NSCLC) is intravenous administration of a platinum doublet.1-2 At the 
same time, the use of anti-metabolite drugs, such as the fluoropyrimidine anti-
cancer agent 5-fluorouracil (5-FU), is an additional option for NSCLC therapy. 
Previously the use of 5-FU was thought to be inappropriate for lung cancer therapy 
because the lung contains high levels of dihydropyrimidine dehydrogenase (DPD), 
which is known to degrade 5-FU.3 However, there are now two types of 5-FU 
derivatives available which avoid the problem of degradation by DPD and can be 
administrated orally. Uracil-tegafur, which combines tegafur (a 5-FU prodrug) and 
uracil in a 1:4 molar ratio, has been approved for the treatment of patients with 
resected NSCLC in Asian countries such as Japan, Korea, Singapore and Thailand. 
Seminal randomized studies showed that adjuvant chemotherapy with uracil-
tegafur improved the prognosis of patients with stage I adenocarcinoma 2 cm or 
greater in size, but not squamous cell carcinoma (SQCC).4, 5 Another 5-FU 
derivative, termed S-1, consists of tegafur and two modulators gimeracil and 
oteracil. Gimeracil is a DPD inhibitor that prevents degradation of 5-FU in the 
body. Oteracil is an orotate phosphoribosyltransferase (OPRT) inhibitor, which 
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decreases the activity of 5-FU in normal gastrointestinal mucosa. The phase II and 
phase III trials of S-1 plus platinum documented that S-1 is effective against both 
adenocarcinoma (ADC) and squamous cell carcinoma (SQCC), suggesting that S-1 
is a valid treatment option.6,7 
EGFR mutation status is well known as a predictor of response to treatment by 
EGFR tyrosine kinase inhibitor (EGFR-TKI) and as the target of EGFR-TKIs.8-10 
In 2007, Suehisa and colleagues reported that adjuvant chemotherapy with uracil-
tegafur significantly prolonged survival rates among patients with EGFR wild-type 
adenocarcinoma but not among patients with EGFR mutant tumors.11 In vitro 
studies also demonstrated that EGFR-wild type cells are more sensitive to 5-FU 
than mutant cells. In the same period, Okabe and colleagues demonstrated that 
combined administration of 5-FU and EGFR-TKI had a synergistic 
antiproliferative effect in vitro on all NSCLC cell lines by the down-regulation of 
thymidylate synthase (TS). 12These two studies indicate that a molecular 
relationship might exist between EGFR mutation status and 5-FU related enzymes. 
However, the results from these two studies seem to be paradoxical in that the 
target populations of EGFR-TKI and 5-FU differ in EGFR mutation status but the 
effects are the same and are synergistic in all NSCLC populations regardless of 
EGFR mutation status. In addition, down regulation of TS alone by EGFR-TKI 
does not seem to explain the phenomenon. In order to explain the discrepancy, it is 
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necessary to determine the relationship between DPD expression and EGFR 
mutation status. 
In the present study, we examined the correlation between EGFR mutation 
status and DPD and TS expression in lung cancer cells and tissues. To verify this 
relationship, we analyzed 47 resected NSCLCs by laser capture microdissection 
and 49 patients with primary NSCLC who were treated with S-1 adjuvant 
chemotherapy. We then evaluated the relation between EGFR mutation status, and 
each of the 5-FU related enzymes and various clinicopathological factors. We also 
investigated the effect of epidermal growth factor (EGF) on DPD expression in 
both EGFR mutated and non-mutated cell lines. 
 
Patients and Methods 
For the laser microdissection study, tumor specimens were obtained from 47 
patients with primary NSCLC who underwent surgery at Nagasaki University 
Hospital from June 1996 to April 2005. The follow up period was 7.3 to 66.4 
months (median 60.9 months for overall and 60.8 months for relapse free). For the 
postoperative S-1 treatment study, a subset of patients was selected from a multi-
center feasibility study that used S-1 as postoperative adjuvant chemotherapy in 
patients with curatively resected pathological stage IB-IIIA NSCLC.13 The follow 
up period was 6.3 to 80.5 months (median 62.7 months for overall and 57.0 months 
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for relapse free). Tumor specimens were obtained from 49 patients from June 2005 
to March 2007. The clinicopathological characteristics of the patients are 
summarized in Table 1. Informed consent for use of the tumor specimens was 
obtained from all patients, and the Ethics Review Board on Clinical Research of 
Nagasaki University Hospital (protocol # 05062433) and each hospital approved 
the study protocol. 
 
Tissue preparation and histopathological evaluation 
The surgically resected tumors were fixed in 10% buffered formalin and 
embedded in paraffin. Representative hematoxylin-eosin-stained sections were 
reviewed. Clinical and pathological diagnoses were categorized and classified 
according to the latest 7th TNM staging system guideline (Union of International 
Cancer Control: UICC. Ver. 7).14,15 Vascular invasion was determined by the 
identification of intravascular tumor clots in the lumen of lymphatic or blood 
vessels, as described previously.16 
 
Mutational analysis for EGFR 
DNA was extracted from 2 to 3 serial, 10-μm-thick sections using the QIAamp 
DNA Mini kit (Qiagen, Tokyo, Japan) according to the protocol described in the 
manufacturer’s instructions. The hot-spot mutations of codon 12 in KRAS and 
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EGFR, along with the 9- to 18-bp deletions in exon 19 and the L858R missense 
mutation in exon 21, were analyzed using the mutant-enriched polymerase chain 
reaction (PCR)-restriction fragment length polymorphism (RFLP) method 
described previously.17 Briefly, in order to examine the mutation in exon 19, we 
used ex19 S-1 and ex19 AS-1 for the 1st PCR. PCR amplification was performed 
with 50 to 100 ng of genomic DNA with Go Taq® Green Master Mix (Promega, 
Madison, WI, USA). We also used ex21 f-s and ex21 r-s to examine the mutation 
in exon 21. DNA was amplified for 35 cycles at 94°C - 30 sec, 60°C - 30 sec, 72°C 
- 30 sec followed by 5 minutes of extension at 72°C in the 1st PCR. For the 1st 
RFLP, the restriction enzyme MseI was used to digest the TTAA sequence in the 
wild-type genes, as this is frequently absent in exon 19 deletion mutants. In 
addition, the restriction enzyme MscI was used to digest the TGGCCA sequence in 
the wild-type genes, since the mutant type L858R in exon 21 is not digested. The 
1st PCR product from these restriction enzymes was incubated at 37°C for 12 
hours. For the 2nd PCR, we used ex19 HR-F and ex19 HR-R to examine the 
mutation in exon 19. To examine the mutation in exon 21, we used ex21 HR-F and 
ex21 r-s. The 1st RFLP product was amplified for 20 cycles at 94°C - 30 sec, 60°C 
- 30 sec, 72°C - 30 sec followed by 5 minutes of extension at 72°C in the 2nd PCR. 
For the 2nd RFLP, the restriction enzyme Sau96I was used to digest the GGNCC 
sequence. Since the wild-type DNA is not digested, even partial digestion of the 
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PCR product indicates the presence of a mutation in exon 21. The 2nd PCR 
product from this restriction enzyme was incubated at 37°C for 12 hours. This step 
was not required for the detection of a mutation in exon 19. After the 2nd PCR or 
2nd RFLP, the product was then analyzed by 6% or 8% Polyacrylamide Gel 
Electrophoresis. Primer pairs used for PCR in this study are shown in 
Supplemental Table 1. 
In order to confirm the accuracy of EGFR mutation status, mutant samples were 
detected with mutant-enriched PCR-RFLP, by nested PCR assay based on the 
direct sequence using a previously described procedure.8 Briefly, ex19seqS-1 and 
ex19seqAS-1 primer pairs were used for the 1st PCR, ex19seqS-2 and ex19seqAS-
2 primer pairs were used for the 2nd PCR to examine a mutation in exon 19. We 
also used ex21seqS-1 and ex21seqAS-1 for the 1st PCR, ex21seqS-2 and 
ex21seqAS-2 for the 2nd PCR to examine a mutation in exon 21. Direct 
sequencing was performed with the 3100 Genetic Analyzer (Applied Biosystems, 
Tokyo, Japan), and the results were analyzed using Sequencing Analysis 5.1.1 
software (Applied Biosystems) to compare variations. The sequences were 
compared with the GenBank sequence for human EGFR (accession number 
NC000007). The entire procedure is summarized in supplemental methods and 
supplemental Figure 1. 
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Mutational analysis for KRAS 
The hot-spot mutations in codon 12 in KRAS were also detected by the mutant-
enriched PCR- direct DNA sequencing method. The 1st PCR was done using the 
primer pairs K-F-2 and K-R-2. DNA was amplified for 35 cycles at 95°C - 30 sec, 
56°C - 30 sec, 72°C - 30 sec followed by 5 minutes of extension at 72°C in the 1st 
PCR. For RFLP, the restriction enzyme MvaI was used to digest the CCA/TGG 
sequence in the wild-type genes, which is not digested in the mutant. The 1st PCR 
product from this restriction enzyme was incubated at 37°C for 12 hours. The 2nd 
PCR was performed using a primer pair K-F-2 and K3-R-2. The RFLP product 
was amplified for 20 cycles at 95°C - 30 sec, 62°C - 30 sec, 72°C - 30 sec followed 
by 5 minutes of extension at 72°C in the 2nd PCR. After the 2nd PCR, the product 
was then analyzed by 2% agarose gel electrophoresis. Direct sequencing was 
performed with the 3100 Genetic Analyzer (Applied Biosystems, Tokyo, Japan), 
and the results were analyzed using Sequencing Analysis 5.1.1 software (Applied 
Biosystems) to compare variations. The sequences were compared with the 
GenBank sequence for human KRAS (accession number NC000012). The 
procedure is summarized in supplemental methods and supplemental Figure 1. 
 
Laser capture microdissection study 
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Using a previously described procedure,18 10-μm-thick sections were stained 
with neutral fast red to enable laser capture microdissection (P.A.L.M. Microlaser 
Technologies AG, Munich, Germany) of tumor cells only. RNA was isolated from 
formalin-fixed, paraffin-embedded specimens using a novel, proprietary procedure 
(Response Genetics, Los Angeles, CA: United States Patent Number 6,248,535). 
After RNA isolation, cDNA was derived from each sample using a previously 
described procedure.19 For the quantitative RT-PCR, the specifics of the procedure 
and primers used were described in our previous report.18,19 
 
Immunohistochemical staining for DPD, and TS 
5-μm-thick sections were prepared for immunohistochemical staining. Details 
of the entire procedure are as described previously.18 The primary polyclonal 
antibodies against DPD and TS were both used at a concentration of 1:1000. These 
antibodies were generously donated by Taiho Pharmaceutical Co, Japan. The 
secondary antibody for DPD was biotinylated anti-rabbit IgG and peroxidase-
labeled streptavidin (Histofine Simple Stain MAX-PO, Nichirei, Tokyo, Japan). 
For TS, the VECTASTAIN Elite ABC kit reagents (Vector Laboratories, 
Burlingame, CA) were used as the secondary antibody. Antibody binding was 
visualized using DAB (DAKO, Santa Barbara, CA). 
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Two pathologists, without knowledge of the clinicopathological data, 
independently evaluated all immunohistochemical staining (Supplemental Figure 
2). 
 
Cell culture study 
The human lung adenocarcinoma cell line, A549 and PC9 were obtained from 
DS Pharma Biomedical (Osaka, Japan) and Immuno-Biological Laboratories 
(Gunma, Japan). NCI-H1975, NCI-H1299 and NCI-H1437 were obtained from the 
American Type Culture Collection (Manassas, VA, USA). In all cell lines, 
mutation screening for EGFR and KRAS was performed as described above. The 
results confirmed that A549 has a G12S point mutation in KRAS, PC9 has a 746-
750 deletion in EGFR exon 19, and H1975 has a L858R point mutation in EGFR 
exon 21. H1299 and H1437 are wild type for both EGFR and KRAS. 
All cells were maintained in RPMI1640 (Invitrogen Japan, Tokyo, Japan). The 
media contained 10% fetal bovine serum, 1% penicillin-streptomycin (Nacalai 
Tesque, Kyoto, Japan), and 2 mM L-glutamine (Invitrogen Japan, Tokyo, Japan). 
Cells were incubated in a humid atmosphere containing 95% air and 5% CO2. 
RNA from cultured cells was extracted using the RNeasy Mini Kit (QIAGEN, 
Tokyo, Japan) and cDNA was produced by the PrimeScript RT Master Mix 
(Takara, Siga, Japan), according to the protocol described in the manufacturer’s 
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instructions. Genomic DNA in the cultured cells was extracted using the 
QuickGene DNA tissue kit S (Fujifilm, Tokyo, Japan), according to the protocol 
described in the manufacturer’s instructions.  
PCR reactions were performed using 20 ng of cDNA with the LightCycler 480 
SYBR Green I Master (Roche Molecular Biochemicals, Indianapolis, IN, USA) 
according to the protocol described in the manufacturer’s instructions. Quantitative 
RT-PCR was performed on a Roche LightCycler 480 system (Roche Molecular 
Biochemicals). The primer pairs used for this RT-PCR are shown in Table S1. 
Cycle conditions consisted of denaturation (95°C - 10 min), 50 cycles of 
amplification (95°C - 10 sec, 60°C - 10 sec, 72°C - 6 sec), melting (95°C - 5 sec, 
65°C - 1 min, 97°C - 0 sec), and cooling (40°C - 30 sec). Quantification data were 
analyzed with the LightCycler analysis software (Roche Molecular Biochemicals). 
 
EGF administration in cell culture study 
Human epidermal growth factor (EGF) was obtained from Cell Signaling 
Technology (Danvers, MA, USA). To examine the relationship between DPD 
expression and EGFR mutation status, we administered various concentrations of 
EGF (0 to 100 ng/ml) to the cell lines. Cells in 2000 μl of culture medium per well 
were seeded into 6-well plates and cultured at 37°C for 24 h. The culture medium 
was then replaced with serum-free medium (RPMI 1640 containing 2mM L-
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glutamine), and 100 μl of PBS containing various amounts of EGF. After 




Cells were washed twice with PBS and lysed in Passive Lysis Buffer (Promega, 
Madison, WI, USA). The lysates were centrifuged at 14,000 rpm for 1 min at 4°C, 
and the protein concentration of the supernatants was determined using the Pierce 
BCA Protein Assay Kit (Thermo scientific, Rockford, IL, USA). For 
immunoblotting, supernatant proteins (10 μg) from cell lysates were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). The 
proteins were blotted onto a polyvinylidene difluoride membrane and incubated 
with anti-DPYD rabbit monoclonal IgG (Cell Signaling Technology, Danvers, MA, 
USA) or anti-actin rabbit polyclonal IgG (Abcam, Cambridge, MA, USA) as the 
primary antibody, followed by horseradish peroxidase-conjugated goat anti-rabbit 
IgG (Amersham, Buckinghamshire, UK). Immunolabeled proteins were visualized 
using the Luminescent Image Analyzer LAS-1000plus (Fujifilm, Tokyo, Japan) 
after incubation with Chemi-Lumi One Super (Nacalai Tesque, Kyoto, Japan). 
 
Statistical analysis 
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The chi-square test was used to analyze associations between EGFR and KRAS 
mutation, DPD and TS immunohistochemical expression, and clinicopathological 
factors associated with S-1 adjuvant chemotherapy. The Kaplan-Meier method was 
used to estimate overall survival (OS) and relapse-free survival (RFS). The log-
rank test was used to test for differences between estimated time-to-event curves. 
Student’s t-test was used to analyze associations between expression of DPD and 
TS mRNA and clinicopathological factors. A P-value of 0.05 was regarded as 
statistically significant and all comparisons were 2-sided. JMP 10.0 statistical 
software (SAS Campus Drive Cary, NC) was used to perform all analysis. 
 
RESULTS 
Correlation among pathology, DPD and TS mRNA levels, and EGFR mutation 
status in NSCLC 
With regard to histopathological types, ADC had significantly higher DPD 
mRNA levels than SQCC (P = .006) (Figure 1). When we subdivided ADC into 
AIS and invasive ADC (including minimally invasive ADC), the difference in 
DPD mRNA levels was more remarkable between AIS and SQCC (P < .001) than 
between ADC and SQCC (P = .247). Although the TS mRNA level found in 
SQCC was slightly higher than that in ADC, we did not detect a significant trend.  
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The Chi-square analysis revealed that AIS had an obviously higher EGFR 
mutation rate than ADC and SQCC (P < .0001) (Table 2). 
 
Correlation between clinicopathological factors and EGFR mutation status and 
immunohistochemical staining for DPD and TS in the specimens obtained from 
the phase II study 
Table 3 shows the relationships between EGFR mutation status and various 
clinicopathological parameters including the immunohistochemical evaluation for 
DPD and TS in NSCLC tissue obtained from patients in the phase II study. EGFR 
mutations were only detected in ADC and were significantly correlated with 
female (P = .017) and non-smoker (P = .001) groups. In the immunohistochemical 
examination, high DPD expression was significantly correlated with female sex (P 
= .003), non-smoking status (P = .019), and EGFR mutation status (P = .003). For 
TS immunostaining, there were no correlations among any of the 
clinicopathological factors including EGFR mutation status. 
 
EGFR mutation status and prognosis 
In the microdissection study, the prognosis of the EGFR mutation positive 
group was significantly better than for the negative group (P = .033) (Figure 2A). 
The 5-year relapse-free survival rate also indicated that the EGFR mutation 
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positive group tended to have a better prognosis than the negative group (P = .084) 
(Figure 2B). Conversely, in the postoperative S-1 administration study, the 
prognoses of the EGFR mutation positive group and negative group were similar 
(P = .921) (Figure 2C). In addition, relapse-free survival rates of the EGFR 
mutation positive and negative group were 63.6% and 71.2% (P = .584) (Figure 
2D). 
 
Basal DPD mRNA and protein expression in human lung adenocarcinoma cell 
lines 
The expression level of DPD mRNA in the lung ADC cell lines was quantified 
by real-time RT-PCR (Figure 3A). The basal DPD mRNA expression levels in the 
EGFR mutant cell lines PC9 and H1975 were higher than that of EGFR wild-type 
cells (P < .003). From western blot analysis, the expression of DPD protein was 
higher in EGFR mutant cells than in EGFR wild-type cells (Figure 3B). 
 
Effects of EGF administration on DPD mRNA expression 
Figure 4 shows the DPD mRNA expression of each cell line after the 
administration of EGF. Of the five cell lines examined, only EGFR mutant cell 
lines had a statistically significant increase in DPD mRNA expression after the 
administration of EGF. In the PC9 cell line, which harbors a deletion of exon 19 
Mochinaga et al.  20 / 34 
(E746-A750) with EGFR amplification,20 DPD mRNA expression significantly 
increased at 0.1 to 1.0 ng/ml added EGF and remained high with increasing 
concentrations of EGF (P = .0006). In H1975 cell lines, which harbor point 
mutations in exon 21 of EGFR (L858R and T790M) but does not have EGFR 
amplification,20 DPD mRNA expression was significantly increased at 0.1 ng/ml 
EGF (P = 0.0083) and decreased at higher concentrations of added EGF thereafter. 
In the EGFR wild-type cell lines, there was no effect on DPD mRNA expression 
with added EGF. 
 
Discussion 
The present studies reveal a clinical correlation between EGFR mutation status 
and DPD expression. Our results demonstrate that higher DPD mRNA expression 
occurs in adenocarcinomas (ADC), especially adenocarcinoma in situ (AIS) 
(Figure 1). These results are consistent with the report of Kaira and colleagues that 
higher DPD expressions were found in adenocarcinomas as compared with non-
adenocarcinomas.21 DPD is a rate-limiting enzyme for degrading 5-FU in the liver 
and other tissues.22 A high level of DPD in tumor cells accelerates inactivation of 
5-FU thus reducing the effectiveness of 5-FU therapy. Therefore, AIS and invasive 
ADC might have differing sensitivities to 5-FU, indicating that these carcinomas 
have different biological properties. This study also shows that a higher frequency 
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of EGFR mutation occurs in AIS (Table 2). This result is accordant with several 
studies that found EGFR gene mutation clusters in bronchioloalveolar carcinoma 
(BAC) (now classified as AIS) and that this characteristic of BAC is a predictor of 
response to EGFR-TKI.23-25 
The clinicopathological analysis revealed that higher DPD protein levels were 
found in females than in males and in non-smokers than in smokers. In our 
previous study, significantly higher DPD mRNA expression and DPD protein 
levels were also correlated with females and non-smokers.18 These two populations 
overlap in the target population of EGFR-TKI therapy.9 Accordingly, a statistically 
significant correlation was observed between EGFR mutation status and DPD 
protein expression (Table 3). These data support the results of Suehisa and 
colleagues that showed sensitivity to 5-FU is lower in EGFR mutant cell lines than 
in EGFR wild-type human lung cancer cell lines.11 Because DPD is a rate-limiting 
enzyme for degradation of 5-FU, patients with EGFR-mutated tumors might not 
respond to uracil-tegafur treatment because of their high DPD activity.  
Our survival data of the microdissection studies indicate that the EGFR 
mutation positive group has a better prognosis than the negative group after 
operation (Figure 2A and 2B). The finding is consistent with previous reports 
indicating that EGFR mutation status is a postoperative predictive marker of a 
good prognosis. 26, 27 However, in the postoperative S-1-treated population, the 
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survival curve of the EGFR mutation positive group overlapped with that of the 
negative group. The explanation is that S-1 might be more effective in patients that 
are EGFR mutation negative, referred to as wild-type, with improved survival rates 
comparable to the level of the EGFR mutation-positive population, thus resulting 
in the same prognosis for both populations. However, given that the 70.7% of 5-
year overall survival rate of the EGFR mutation positive group is favorable in stage 
IB to IIIA patients, there is a possibility that S-1 might be able to suppress 5-FU 
degradation in EGFR mutated tumors with high DPD because S-1 has 180 times 
higher DPD suppressive effect than uracil-tegafur. As a result, S-1 postoperative 
treatment might show some prognostic improvement even in EGFR mutant 
populations. Survival differences classified by TS expression or DPD expression 
might be of interest. However, there was no significant survival difference between 
the DPD positive and negative groups and the TS-positive and negative groups in 
both cohorts of the microdissection study and the postoperative S-1-treated study 
(data not shown). 
Okabe and colleagues concluded that the suppression of TS by EGFR-TKI 
induced the synergistic antitumor effect with 5-FU and EGFR-TKI.12 Using a nude 
mouse NSCLC model, they demonstrated that both single S-1 and S-1 plus EGFR-
TKI exerted antitumor effects on lung cancer cell lines regardless of EGFR 
mutation status.12 However, they did not mention the strong DPD inhibitory effect 
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of S-1 which might affect the antitumor efficacy of 5-FU in lung cancer cell lines. 
Our results indicate that high DPD activity is another key factor determining the 
effectiveness of 5-FU derivatives in EGFR mutant populations and cells. The real 
synergetic effect could be established by doing clinical studies, as well as treated 
samples, using the combination of both S-1 and EGFR-TKI. 
Phosphorylation of EGFR is responsible for activation of JAK-STAT, MAP 
kinase, and the Phosphatidylinositol-3 kinase/AKT signal cascade, which regulates 
a variety of proteins. Because AIS tends to have high EGFR mutation rates with 
higher DPD mRNA levels, it is likely that an unknown mechanism for molecular 
regulation exists between the EGFR cascade and DPD expression, similar to the 
correlation between EGFR signal transduction and TS expression.12 In this study, 
no trend was observed when comparing TS mRNA levels in EGFR mutated or 
wild type cell lines, or in the EGF administration exam (data not shown). 
Interestingly, EGFR mutated cell lines showed high DPD mRNA and protein 
expression in base line (Figure 3). Further, EGF administration caused a fluctuation 
in DPD mRNA expression in EGFR mutant cell lines but not in wild-type cell lines 
(Figure 4). This result is consistent with the report of Sordella and colleagues that 
EGF phosphorylates different parts of the EGFR C-terminal tyrosine residues 
between EGFR wild-type and mutant, and thus, it activates selective downstream 
signaling pathways.28 It is curious that administration of an EGF dose below or 
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equal to 1 ng/ml resulted in an increase in DPD expression, but EGF 
concentrations above 1 ng/ml caused a decrease in DPD expression. This same 
phenomenon was observed by Kashima et al. using uterine cervical carcinoma 
SKG-IIIB cells 29. It is likely, as the authors in that report speculate, that the 
anabolic pathway became dominant in cells with stimulated growth and that DPD, 
an enzyme of the catabolic pathway, was inhibited at a higher EGF concentration. 
29 
There are some limitations in this study. First, our sample size may not be large 
enough to discuss the prognostic analysis. Larger scale analysis might be necessary 
to elucidate the prognostic impact of EGFR mutation status for S-1 treated 
populations. Second, although we did not test for other 5-FU related genes in this 
study, such additional information is unlikely to be sufficient to explain the lack of 
5-FU efficacy as this depends on many genes in the 5-FU pathway. Detailed 
studies of signal cascades in DPD transcriptional regulation should be undertaken. 
Published analysis of the DPD promoter identified several potential cis- acting 
regulatory elements including binding sites for transcription factors Sp-1, AP-2, 
NF-kB, and Egr families.30,31 Further studies are necessary to clarify the crosstalk 
between EGFR signaling and DPD transcription.   
 
Conclusion 
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High DPD expression was shown to be correlated with EGFR mutation in 
adenocarcinoma. In particular, AIS had both high DPD mRNA expression and high 
EGFR mutation frequency. Given that EGFR mutant cells had higher DPD mRNA 
and protein levels, and EGF administration increased DPD mRNA in such cell 
lines, DPD activity might be another key factor determining the effectiveness of 5-
FU derivatives in EGFR mutant populations and cells. Further analysis about 
transcriptional regulation of the EGFR cascade and DPD expression should be 
investigated. 
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Clinical practice points 
 Previously the use of 5-FU was thought to be inappropriate for lung cancer 
therapy. However, in Asian countries, there are now two types of 5-FU 
derivatives, which avoid the problem of degradation by dihydropyrimidine 
dehydrogenase (DPD), are now approved and available as an option for 
NSCLC therapy. It has been shown that EGFR mutation status affects the 
efficacy of the 5-FU derivatives for NSCLC treatment. However, the effects of 
EGFR mutation status on DPD expression have not been elucidated.  
 The major findings of the present study were the positive correlation between 
DPD expression and EGFR mutations. Histologically, higher DPD mRNA 
expression occurs in adenocarcinomas, especially adenocarcinoma in situ (AIS). 
In addition, AIS showed a significantly higher EGFR mutation frequency than 
other histological types. Clinically, DPD immuno-positive cases were more 
frequently observed in females and in non-smokers, which are overlapping 
EGFR mutated populations. Accordingly, DPD immune-positive cases were 
correlated with EGFR mutation status. The cell culture based study also 
revealed high DPD mRNA and protein expression in EGFR mutated cell lines 
and that added EGF increases DPD mRNA only in such cell lines. This finding 
indicates that DPD regulation might be different depending on EGFR mutation 
status. 
Mochinaga et al.  27 / 34 
 The clinical impact of these results is to help select the appropriate treatment 
for NSCLC considering the effect of EGFR mutation status on 5-FU treatment. 
The present study indicates that 5-FU derivatives might have more benefit for 
EGFR mutation negative populations and less benefit for EGFR mutation 
positive populations because of DPD activity in NSCLC. 
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Figure legends 
 
Fig. 1.  Box-and-whisker plots of mRNA levels according to histopathological 
type. Lines within the boxes represent median values; the upper and lower lines of 
the boxes represent the 25th and 75th percentiles, respectively, and the upper and 
lower bars outside the boxes represent the 90th and 10th percentiles, respectively. 
The dots represent outlier values. p -values were evaluated by Student t-test using 
log (data) (p < 0.05). 
 
Fig. 2.  Kaplan-Meier overall and relapse free survival curves for all patients 
according to EGFR mutation status in the laser microdissection study (n = 47; the 
follow up period was 7.3 to 66.4 months) (A and B) and postoperative S-1 treated 
study (n = 49; the follow up period was 6.3 to 80.5 months) (C and D).  
 
Fig. 3.  Relative DPD mRNA expression ratio compared to β-actin (A) and 
Western blot analysis (B) in the KRAS mutation-positive cell line (A549), EGFR 
mutation-positive cell lines (PC9 and H1975), and wild-type cell lines (H1299 and 
H1437) (n = 5). 
 
Fig. 4.  Effects of EGF on DPD mRNA expression in each cell line (n = 4). Low 
concentration of EGF increased DPD mRNA level in EGFR-mutated cell lines 
Mochinaga et al.  2 / 2 
(PC9 and H1975). The dots represent outlier values (p < 0.05). EGF had no effect 
on DPD mRNA level in KRAS mutation-positive cell line (A549) and in EGFR 
mutation wild-type cell lines (H1299 and H1437).  
 
Supplemental Fig. 1.  Flow chart of the mutation analysis. Details of the entire 
procedure are provided in the supplemental methods. 
 
Supplemental Fig. 2.  Immunohistochemical staining. The intensity of staining 
was classified as 0 (no staining), +1 (weak staining), +2 (distinct staining), or +3 
(very strong staining). Grades 0 and 1 were further categorized as negative, and 



























































































































The number of patients at risk at the indicated time
EGFR mutation 24 23 20 18
EGFR wild 23 20 14 10
The number of patients at risk at the indicated time
EGFR mutation 24 21 19 17
EGFR wild 23 15 12 9
Months
The number of patients at risk at the indicated time
EGFR mutation 12 12 11 8
EGFR wild 37 35 31 22
The number of patients at risk at the indicated time
EGFR mutation 12 11 7 6
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Method Flow Chart for Mutation Analysis
1. DNA extraction
2. Mutant-enriched PCR-RFLP















Table 1. Clinicopathological Data of Patients  
Characteristic  Microdissection study (n = 47) S-1 study (n = 49) 
Gender   
    Male 34 34 
    Female 13 15 
Age (years)   
    ≥ 70 24 27 
    < 70 23 22 
Smoking   
    Current or 
former 
34 38 
    Never 13 11 
Histopathology   
    ADC (AIS) 34 (20) 30 (0) 
    SQCC 13 16 
    AD-SQC 0 2 
    Carcinoid 0 1 
Differentiation   
    Well 23 10a 
    Moderate  18 36a 
    Poor 6 0a 
Pathological Stage   
    IA 28 0 
    IB 10 26 
    IIA 0 15 
    IIB 3 1 
    IIIA 4 7 
    IIIB 2 0 
Abbreviations: ADC; adenocarcinoma, AIS; adenocarcinoma in situ, SQCC; squamous cell 
carcinoma, AD-SQC; adenosquamous cell carcinoma 
aThere was no information about differentiation in three cases (2 cases of adenosquamous 
carcinoma and one carcinoid). 
Table 2. Correlation Between EGFR Mutation Status and Pathological Histology in Patients with 




 (n = 20) 
Invasive ADC 
 (n = 44) 
SQCC 




      
    Positive 17 17 2  
< 0.0001 
    Negative 3 27 27  
            
A chi-square test for independence. 47 cases in the microdissection study and 46 cases in the postoperative 
S-1 treated study were combined. Three patients with carcinoid (n = 1) or adenosquamous cell carcinoma 
(n = 2) were excluded. Abbreviations: AIS; adenocarcinoma in situ, ADC; adenocarcinoma (invasive 
ADC including 3 minimally invasive ADC), SQCC; squamous cell carcinoma, EGFR; epidermal growth 
factor receptor 
 
             
Table 3. Correlation among Clinicopathological Characteristics, EGFR Mutation Status, and Immunohistochemical Expression of DPD or TS in 
Patients with NSCLC in S-1 Phase II Study (n = 49) 
    EGFR mutation  DPD  TS 
Characteristics 
No. of Mutant Wild 
p 
 Positive Negative 
p 
 Positive Negative 
p 
patients 12 37   10 39   16 33 
Gender             
    Male 34 5 29 0.017a  3 31 0.003a  12 22 0.553 
    Female 15 7 8   7 8   4 11  
Age, Years             
    ≥ 70 27 5 22 0.282  5 22 0.716  11 16 0.181 
   ＜70 22 7 15   5 17   5 17  
Smoking             
    Never 11 6 5 0.001a  5 6 0.019a  4 7 0.766 
    Current or former 38 6 32   2 23   12 26  
Histology             
    ADC 30 12 18 0.002a  8 22 0.172  10 20 0.899 
    Non-ADC 19 0 19   2 17   6 13  
Tumor status             
    pT1 12 3 9 0.962  3 9 0.650  3 9 0.515 
    pT2-3 37 9 28   7 30   13 24  
Nodal Status             
    pN0 28 7 21 0.924  6 22 0.838  11 17 0.253 
    pN1-2 21 5 16   4 17   5 16  
Lymphatic invasion             
    Negative 44 11 33 0.805  8 36 0.251  14 30 0.712 
    Positive 5 1 4   2 3   2 3  
Vessel invasion             
    Negative 42 11 31 0.498  9 33 0.664  13 29 0.534 
    Positive 7 1 6   1 6   3 4  
Differentiation             
    Well 10 5 5   2 8   4 6  
    Moderately 24 6 18 0.070  5 19 0.981  6 18 0.581 
    Poorly 13 1 12   3 10   5 8  
EGFR             
    Mutant 12 (-) (-)   6 6 0.003a  2 10 0.174 
    Wild 37 (-) (-)   4 33   14 23  
KRAS             
    Mutant 14 2 12 0.294  3 11 0.911  3 11 0.289 
    Wild 35 10 25     7 28     13 22   
A chi-square test for independence (＊P value < 0.05). Abbreviations: EGFR; epidermal growth factor receptor, KRAS; Kirsten rat sarcoma 2 viral oncogene 
homolog, DPD; dihydropyrimidine dehydrogenase, TS; thymidylate synthase, ADC; adenocarcinoma 
 
Supplemental Table 1. Sequences of Primers Used for PCR in Each Method 
Primer Sequence 
For mutant-enriched PCR-RFLP 
 ex19 S-1 ATCCCAGAAGGTGAGAAAGATAAAATTC 
 ex19 AS-1  CCTGAGGTTCAGAGCCATGGA 
 ex19 HR-F AAAATTCCCGTCGCTATCA 
 ex19 HR-R AAGCAGAAACTCACATCG 
   
 ex21 f-s  CGCAGCATGTCAAGATCACAG 
 ex21 r-s ACTTTGCCTCCTTCTGCATGG 
 ex21 HR-F AGATCACAGATTTTGGGC 
   
 K-F-2 AACTTGTGGTAGTTGGACCT 
 K-R-2 TCAAAGAATGGTCCTGCACC 
 K3-R-2 GGTCCTGCACCAGTAATATG 
   
For PCR-direct DNA sequencing 
 ex19seqAS-1 CATAGAAAGTGAACATTTAGGATGTG 
 ex19seqS-2 CCTTAGGTGCGGCTCCACAGC 
 ex19seqAS-2 CATTTAGGATGTGGAGATGAGC 
   
 ex21seqS-1 CTAACGTTCGCCAGCCATAAGTCC 
 ex21seqAS-1 GCTGCGAGCTCACCCAGAATGTCTGG 
 ex21seqS-2 CAGCCATAAGTCCTCGACGTGG 
 ex21seqAS-2 CATCCTCCCCTGCATGTGTTAAAC 
   
For RT-RCR  
 DPD-S GTTGTGGCTATGATTGATGA 
 DPD-AS ATTCACAGATAAGGGTACGC 
 β-actin-S GCAAAGACCTGTACGCCAAC 
  β-actin-AS CTAGAAGCATTTGCGGTGGA 
Abbreviations: RFLP; restriction fragment length polymorphism, RT; reverse 
transcription, DPD; dihydropyrimidine dehydrogenase 
 




    Oveall Survival 
 
Relapse Free Survival 
    Number of patients   %Survival   P-value   %Survival   P-value 
Age (years) 





78.3 ± 0.1 
 0.611   
81.3 ± 0.1 





66.8 ± 0.1 
  
76.4 ± 0.1 
 
           Gender 
          




65.1 ± 0.1 
 0.109   
74.1 ± 0.1 
 0.262  




91.7 ± 0.1 
  
91.7 ± 0.1 
 
           Smoking 
          




64.6 ± 0.1 
 0.092   
73.3 ± 0.1 
 0.221  




92.3 ± 0.1 
  
91.7 ± 0.1 
 
           Histology 
          




80.8 ± 0.1 
 0.016   
78.3 ± 0.1 
 0.867  




46.4 ± 0.2 
  
81.8 ± 0.1 
 
           Tumor Status 
          




86.0 ± 0.1 
 0.007   
92.7 ± 0.0 
 0.010  




46.5 ± 0.1 
  
58.3 ± 0.1 
 
           Nodal Status 
          




75.6 ± 0.1 
 0.190   
80.7 ± 0.1 
 0.352  




51.4 ± 0.2 
  
66.7 ± 0.2 
 
           Lymphatic Invasion 
          




100.0 ± 0.0 
 <0.001  
100.0 ± 0.0 
 0.001  




47.0 ± 0.1 
  
56.6 ± 0.1 
 
           Vessel Invasion 
          




82.2 ± 0.1 
 0.007   
83.4 ± 0.1 
 0.203  




49.9 ± 0.1 
  
67.1 ± 0.1 
 
           Differentiation 
          




95.2 ± 0.0 
 0.002   
95.2 ± 0.0 
 0.009  




51.9 ± 0.1 
  
61.8 ± 0.1 
 
           EGFR Mutaion 
          




87.0 ± 0.1 
 0.033   
87.0 ± 0.1 
 0.084  
  Wild type   23   55.2 ± 0.1     61.5 ± 0.1   
Logrank test for independence, Data are mean ± S.D., EGFR: epidermal growth factor receptor 
   
 
